CTRI/2009/091/000578已完成3 期
A Multicenter, Open Label, Active Control, Parallel-Group Randomized Study to Demonstrate Non Inferiority of Brinzolamide 1% Ophthalmic Suspension compared With Dorzox (Dorzolamide) 2% Ophthalmic Solution in Treatment of Elevated Intra-Ocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension
Alcon Laboratories India Pvt Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male and females 18 years of age or older, diagnosed with primary open-angle glaucoma or ocular hypertension.
- •2.IOP measurements ≥ 24 ≤ 36 mm Hg, in atleast one eye, at 9.00 am and ≥ 21 ≤ 36 mm Hg in atleast one eye (the same eye) at 11.00 am measurement
排除标准
- •Patients with one sighted eye or amblyopia, history of chronic or recurrent inflammatory eye disease, ocular infections (3 months), ocular trauma, severe or progressive retinal or optic nerve disease, severe ocular pathology, intraocular surgery (last 12 months), laser surgery (last 3 months), current use of steroids or presence of any other form of glaucoma other than primary open angle glaucoma
研究者
相似试验
已完成
3 期
CLINICAL TRIAL OF ELETRIPTAN TO TREAT ACUTE MIGRAINE ATTACKS IN ADULT PATIENTSCTRI/2010/091/000425Intas Pharmaceuticals Limited240
尚未招募
不适用
A study on the efficacy and safety evaluation betweenAutologous Chondrocytes Implantation with CartiLife versus Microfracture for Patients with Knee Chondral DefectsDiseases of the musculo-skeletal system and connective tissueKCT0004966Biosolutions104
招募中
不适用
Study to assess the efficacy and safety of treatment of articular cartilage lesions with CartiLife®.Diseases of the musculo-skeletal system and connective tissueKCT0001577MCTTBio30
已完成
不适用
SMART MUMS WITH SMART PHONES 2 (SMs2) Text messaging support for women after gestational diabetesACTRN12620000615987niversity of Sydney177
进行中（未招募）
不适用
Clinical research study to assess the safety and effectiveness of alpha1-proteinase inhibitor (A1-PI) administered by intravenous application to patients with alpha1-proteinase deficiency and emphysema who have completed the 2-year treatment and observation period in the Phase III/IV Zemaira® CE1226_4001.Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.MedDRA version: 16.0Level: LLTClassification code 10001811Term: Alpha-1 proteinase inhibitor deficiencySystem Organ Class: 100000004850EUCTR2007-007129-38-CZCSL Behring GmbH140